Position in JUNS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$445
-$615 QoQ
Shares Held
2,082
-26.2% QoQ
Ownership
0.270%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#3
of 13 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JUNS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GEODE CAPITAL MANAGEMENT, LLC holds $22,039,427,018 across 520 Biotechnology names. JUNS ranks #517 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
6,017,848 | $2,989,245,636 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,625,810 | $1,637,297,566 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,635,840 | $793,466,914 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
3,942,676 | $738,384,360 | |
| 5 | MRNA |
Moderna, Inc.
|
9,710,335 | $680,014,759 | |
| 6 | INCY |
Incyte Corp
|
4,750,735 | $538,543,319 | |
| 7 | RPRX |
Royalty Pharma plc
|
8,058,048 | $451,814,751 | |
| 8 | INSM |
INSMED Inc
|
4,220,155 | $449,952,925 |
All Filings in JUNS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $445 | 156,127 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $1,060 | 211,696 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $1,803 | 132,641 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $2,436 | 103,815 | Shares | Defined | 2025-11-12 | |
| No filing history on record for this holder in this stock. | ||||||